Advertisement
Screener

Serina Therapeutics, Inc. (SER) Return on Tangible Equity

2.8 / 5 stars · 68/120 Roast Me

Serina Therapeutics, Inc. Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Serina Therapeutics, Inc. return tang equity for the quarter ending 2026-06-30 was -116.21%, a change of 991.18% year-over-year.
  • Serina Therapeutics, Inc. return tang equity for the quarter ending 2026-03-31 was -124.23%, a change of -34.80% year-over-year.
  • Serina Therapeutics, Inc. return tang equity for the quarter ending 2025-12-31 was 3513.19%, a 99.68% decline year-over-year.
  • Serina Therapeutics, Inc. return tang equity for the quarter ending 2025-09-30 was -1713.00%, a 3441.39% decline year-over-year.
  • Serina Therapeutics, Inc. return tang equity for fiscal 2025 was 2978.57%, a 73.53% decline from fiscal 2024.
  • Serina Therapeutics, Inc. return tang equity for fiscal 2024 was 11253.54%, a change of 11269.55% from fiscal 2023.
  • Serina Therapeutics, Inc. return tang equity for fiscal 2023 was -16.01%, a 158.76% decline from fiscal 2022.
  • Serina Therapeutics, Inc. return tang equity for fiscal 2022 was 27.26%, a 59.96% decline from fiscal 2021.
Available history
2017-12-31 to 2026-06-30
Data captured

Historical Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-06-30-116.21%-$21.18M$18.22M
2026-03-31-124.23%-$21.27M$17.12M
2025-12-313513.19%-$19.18M-$546,000.00
2025-09-30-1713.00%-$18.59M$1.09M
2025-06-30-1107.39%-$12.59M$1.14M
2025-03-31-89.43%-$939,000.00$1.05M
2024-12-311114100.00%-$11.14M-$1,000.00
2024-09-3051.27%-$7.35M-$14.34M
2024-06-3041.38%-$7.01M-$16.93M
2024-03-3139.38%-$11.4M-$28.96M
2023-12-31-16.00%$5.27M-$32.93M
2023-09-30-4.46%$1.52M-$33.99M
2023-06-307.43%-$2.67M-$35.96M
2023-03-3116.60%-$6.1M-$36.73M
2022-12-3127.26%-$10.46M-$38.39M
2022-09-3062.04%-$9.92M-$15.99M
2022-06-3066.93%-$9.44M-$14.1M
2022-03-3174.77%-$9.29M-$12.43M
2021-12-3168.07%-$8.68M-$12.75M
2021-09-3082.38%-$8.96M-$10.88M
2021-06-30103.49%-$9.55M-$9.23M
2021-03-31138.11%-$9.77M-$7.07M
2020-12-31155.48%-$10.87M-$6.99M
2020-09-30203.18%-$11.13M-$5.48M
2020-06-30295.64%-$11.81M-$3.99M
2020-03-31511.65%-$12.21M-$2.39M
2019-12-31-2608.15%-$12.15M$466,000.00
2019-09-30-476.03%-$12.63M$2.65M
2019-06-30-232.25%-$11.56M$4.98M
2019-03-31-139.47%-$10.4M$7.46M
2018-12-31-135.86%-$7.5M$5.52M

Annual Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2025-12-312978.57%-$19.18M-$644,000.00
2024-12-3111253.54%-$11.14M-$99,000.00
2023-12-31-16.01%$5.27M-$32.9M
2022-12-3127.26%-$10.46M-$38.39M
2021-12-3168.07%-$8.68M-$12.75M
2020-12-31155.48%-$10.87M-$6.99M
2019-12-31-2608.15%-$12.15M$466,000.00
2018-12-31-135.86%-$7.5M$5.52M
2017-12-31-102.09%-$6.58M$6.45M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Clene Inc. (CLNN)United States$0.054B-1.99
HERON THERAPEUTICS, INC. /DE/ (HRTX)United States$0.055B-2.38
Xilio Therapeutics, Inc. (XLO)United States$0.052B
Annovis Bio, Inc. (ANVS)United States$0.056B-1.58
NOMAD POWER SOLUTIONS, INC. (NMAD)United States$0.058B
Boundless Bio, Inc. (BOLD)United States$0.059B-0.88
Elicio Therapeutics, Inc. (ELTX)United States$0.049B
Lite Strategy, Inc. (LITS)United States$0.049B
Dogwood Therapeutics, Inc. (DWTX)United States$0.049B
TALPHERA, INC. (TLPH)United States$0.060B